Pharma BD Deal Intelligence
Celgene acquired Impact Biomedicines for up to $7B for fedratinib.
Celgene Corporation is acquiring Impact Biomedicines in a deal valued at up to $7 billion, gaining fedratinib for treatment of myeloproliferative neoplasms…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Celgene acquired Impact Biomedicines for up to $7B for fedratinib.
3K US cases/yr · $3.0B Global myelofibrosis therapeutics
Myelofibrosis is a chronic myeloproliferative neoplasm with bone marrow fibrosis and splenomegaly. JAK inhibitors are the mainstay of treatment. Fedratinib was approved as second JAK inhibitor option.
First-line: ruxolitinib. Second-line: fedratinib, pacritinib, momelotinib. Allo-SCT for eligible patients. Key players: Novartis (Jakafi/ruxolitinib), BMS (Inrebic/fedratinib), CTI (Vonjo/pacritinib), GSK (Ojjaara/momelotinib).
Celgene paid $1.1B upfront with up to $5.9B in milestones for fedratinib JAK2 inhibitor for myelofibrosis.
Inrebic approved for intermediate-2/high-risk myelofibrosis, first new MF drug in nearly a decade.
BMS closed $74B Celgene deal, gaining Inrebic among the portfolio assets. Part of Celgene Corporation's $7B deal to acquire Impact Biomedicines.
Inrebic generated modest sales vs Jakafi dominant $1B+ position in myelofibrosis market.
Approved but Commercially Modest. Assessment of Celgene Corporation's $7B acquisition of Impact Biomedicines and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Impact Biomedicines (this deal) | 2018 | $7.0B | 54 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Gloucester Pharmaceuticals, Inc. | 2009 | $640M | 40 |
← Browse all deals · How we score deals
More: 2018 deals · Celgene Corporation deals · Oncology deals